Huadong Medicine (SHE: 000963) announced that its wholly‑owned subsidiary, Sinclair Aesthetics (Hangzhou) Medical Technology Co., Ltd., has officially signed a strategic cooperation agreement with Beijing Maybio Biomedical Science and Technology Development Co., Ltd. and Hunan Maybio Biomedical Co., Ltd. (collectively, “Maybio“), securing exclusive strategic collaboration for the extracellular matrix (ECM) collagen product MB007 in the Chinese market.
Deal Snapshot
| Item | Detail |
|---|---|
| Partners | Sinclair Aesthetics (Hangzhou) Medical Technology Co., Ltd. (Huadong Medicine subsidiary) and Maybio (Beijing Maybio Biomedical + Hunan Maybio Biomedical) |
| Agreement Type | Strategic cooperation agreement – exclusive strategic collaboration |
| Product | MB007, iPSC‑engineered ECM collagen |
| Territory | Chinese market (exclusive) |
| Therapeutic Field | Regenerative medical materials / aesthetics |
| Financial Terms | Not disclosed |
| Announcement Date | 17 Sep 2026 |
Technology Profile – Maybio’s iPSC‑Engineered ECM Platform
- Company Focus: Maybio is an innovative enterprise dedicated to induced pluripotent stem cell (iPSC)‑engineered ECM regenerative medical materials.
- Core Technology: Driven by its breakthrough chemically induced pluripotent stem cell (CiPSC) technology, Maybio utilizes licensed iPSC cell lines as seed cells for engineered ECM production.
- Structural Advantages: Compared with traditional ECM, the iPSC‑engineered ECM platform circumvents ethical controversies and raw material sourcing restrictions at the source, while overcoming industry pain points such as limited production capacity and heterogeneous composition.
- MB007 Manufacturing: The ECM collagen product is cultured and extracted using Maybio’s independently developed engineered cell in vitro expression technology.
- Molecular Fidelity: MB007’s core ECM collagen component features a full‑length sequence completely identical to the human sequence, with a complete tertiary structure and quaternary conformation – delivering higher homology, good biocompatibility and bioactivity, and enabling more natural and lasting mechanical support and regenerative stimulation.
Market Impact & Outlook
- Regenerative Aesthetics Landscape: MB007 positions Sinclair within China’s fast‑evolving biostimulatory and regenerative aesthetics segment, where collagen‑based products are moving beyond traditional animal‑derived or recombinant‑fragment formats toward structurally complete, human‑identical ECM materials.
- Sinclair’s China Platform: The exclusive collaboration leverages Sinclair’s established aesthetics commercialization infrastructure in China – the distribution and clinical‑marketing engine behind Huadong Medicine’s medical aesthetics franchise – to bring Maybio’s technology to market.
- Supply‑Chain Differentiation: iPSC‑engineered production addresses two structural constraints of conventional ECM sourcing – raw material supply and batch heterogeneity – a potential scalability and quality‑consistency advantage for commercial‑stage manufacturing.
- Partner Validation: For Maybio, an exclusive tie‑up with a listed pharmaceutical group’s aesthetics arm validates the CiPSC‑based ECM platform and provides a route to clinical development and commercialization in China.
- Regulatory & Development Pathway: MB007’s regulatory classification, clinical trial plans, timelines, and deal economics were Not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the strategic cooperation between Sinclair Aesthetics (Hangzhou) and Maybio, including the development, regulatory pathway, and commercialization of MB007 in the Chinese market. Actual results may differ materially due to risks including clinical and regulatory outcomes, manufacturing scale‑up, market adoption, and competitive dynamics. No product arising from this collaboration has received any marketing authorization.-Fineline Info & Tech
